Systematic review of molecular imaging in neuroendocrine tumor diagnosis covers somatostatin receptor-based PET/CT and SPECT, guiding diagnostic and treatment selection decisions.
Key findingSystematic review of molecular imaging in neuroendocrine tumor diagnosis covers somatostatin recepto
What the researchers found
Systematic review of molecular imaging in neuroendocrine tumor diagnosis covers somatostatin receptor-based PET/CT and SPECT, guiding diagnostic and treatment selection decisions.
Why it matters
Relevant to peptide-based therapeutic applications.
The numbers in context
Systematic review examining diagnostic accuracy of multiple molecular imaging modalities for CUP-NETs.
How the study worked
Methodology in publication.
Who was studied
Patients with neuroendocrine tumors of unknown primary origin across reviewed imaging studies
What this study cannot tell us
Limitations in publication.
How to read the evidence
Based on study design.
When this study was published
Published in 2025.
The bigger picture
Contributes to peptide therapeutic evidence.
Questions still open
- Long-term implications?
- Comparison to evidence?
- Next research?
Common questions
What does this mean?
How reliable?
Read the original research
Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs.
EJNMMI reports, 9(1), 38
Citation
Alonzo, Laura; Cannella, Roberto; Laudicella, Riccardo; Benfante, Viviana; Purpura, Pierpaolo; Micci, Giuseppe; Galia, Massimo; Brancatelli, Giuseppe; Midiri, Massimo; Alongi, Pierpaolo. (2025). Molecular imaging in the diagnostic process of neuroendocrine tumors: a systematic review on unknown primary origin and suspected NETs.. EJNMMI reports, 9(1), 38. https://doi.org/10.1186/s41824-025-00274-4